Growing number of cell and gene therapies setting the industry up for substantial growth

Dublin, Oct 6, 2022 (GLOBE NEWSWIRE) — The “Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Market by Scale of Operation, Vector Type, Application Area, Therapeutic Area and Geographic Regions: Trends Industry and Global Forecasts, 2022-2035” has been added to ResearchAndMarkets.com offering.

With the increasing number of cell and gene therapies being developed and launched for a wide range of therapeutic areas, these modalities are on track to become one of the highest value markets in the biopharmaceutical domain. In fact, in 2021, cell and gene therapy developers raised more than $20 billion worth of capital, marking a 19% increase over the amount raised in 2020 (~$17 billion).

Notably, in February 2022, the USFDA approved the second CAR-T therapy, CARVYKTIT, developed by Johnson and Johnson, which can be used to treat relapsed or refractory multiple myeloma. In addition, nearly 1,500 clinical trials are being carried out worldwide for the evaluation of cell and gene therapies. Over time, it has been observed that the clinical success of these therapies depends on the design and type of gene delivery vector used (in the development and/or delivery of the therapy). Currently, several innovative companies are actively involved in the development/production of viral vectors and/or non-viral vectors for cell and gene therapies.

In this context, it is worth mentioning that, in recent years, multiple vaccine candidates based on viral vectors and non-viral vectors have been developed against COVID-19 (caused by the new coronavirus, SARS-CoV-2) and oncological disorders. ; this is indicative of lucrative opportunities for companies that have the requisite capabilities for viral vector manufacturing and gene therapy manufacturing.

The landscape of viral and non-viral vector manufacturing features a mix of industry players (well-established companies, medium-sized companies, and start-ups/small companies), as well as several academic institutes. It should be noted that a number of companies have emerged in this domain that have the capabilities and facilities to manufacture vectors both for internal requirements and to offer contract services (primarily to ensure optimal use of their resources and open up additional revenue-generating opportunities). ). .

the story continues

Furthermore, to produce more effective and affordable vectors, several novel technologies are being integrated by various stakeholders; these technologies are likely to improve the scalability and quality of the resulting therapy. Furthermore, this industry has also witnessed a significant increase in partnership and expansion activities in recent years, with several companies being acquired by the larger firms. Given the increasing demand for interventions that require genetic modification, the gene therapy and vector manufacturing market is poised to witness substantial growth in the anticipated future.

Scope of the Report

The “Viral Vector Manufacturing, Non-Viral Vector Manufacturing, and Gene Therapy Manufacturing (5th Edition) Market by Scale of Operation (Preclinical, Clinical, and Commercial), Vector Type (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccines), Therapeutic Area (Oncological Pathologies, Rare Pathologies, Neurological Pathologies, Sensory Pathologies, Metabolic Pathologies, Musco-skeletal Pathologies, Blood Pathologies, Immunological Pathologies , and Others), and Geographic Regions (North America, Europe, Asia Pacific, MENA, Latin America, and the Rest of the World): Global Industry Trends and Forecasts, 2022-2035″, the report presents an extensive study of the market fast-growing vector and gene therapy manufacturing, focusing on contract manufacturers as well as companies that have in-house manufacturing facilities yes

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MANUFACTURERS OF VIRAL VECTORS AND GENE THERAPY (INDUSTRY ACTORS): MARKET OVERVIEW

5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET OVERVIEW

6. MANUFACTURERS OF VECTORS AND GENE THERAPY (NON-INDUSTRIAL PARTICIPANTS): MARKET OVERVIEW

7. GENE AND VECTOR THERAPY MANUFACTURING TECHNOLOGIES: MARKET OVERVIEW

8. ANALYSIS OF COMPETITIVENESS OF THE COMPANY

9. MANUFACTURERS OF VECTORS AND GENE THERAPY IN NORTH AMERICA

10. MANUFACTURERS OF VECTORS AND GENE THERAPY IN EUROPE

11. MANUFACTURERS OF VECTORS AND GENE THERAPY IN ASIA-PACIFIC

12. OTHER KEY PLAYERS

13. RECENT ASSOCIATIONS

14. RECENT EXPANSIONS

15. ANALYSIS OF STRATEGIC PARTNERS

16. EMERGING VECTORS

17. KEY PERSPECTIVES

18. COST PRICE ANALYSIS

19. CAPACITY ANALYSIS

20. DEMAND ANALYSIS

21. MARKET SIZE AND OPPORTUNITY ANALYSIS

22. PORTER’S FIVE FORCES ANALYSIS

23. KEY DRIVERS AND CHALLENGES

24. SURVEY ANALYSIS

25. FINAL REMARKS

26. EXECUTIVE PERSPECTIVES

Companies mentioned

• 4D Molecular Therapeutics

• avantibio

• abbot

• AbbVie

• Abeona Therapeutics

• Abintus Bio

• apceth biopharmacy

• Applied Biological Materials

• Applied Genetic Technologies (AGTC)

• Applied Viromics

• arcellx

• ArcticZymes Technologies

• international area

• Aruvante Sciences

• ASC Therapeutics

• QuestionBio

• Asklepios Biopharmaceutical

• Astellas Pharma

• AstraZeneca

• Atara Biotherapeutics

• Atlantic Bio GMP (subsidiary of Atlanpole Biotherapies)

• Atsena Therapeutics

• Audentes Therapeutics (acquired by Astella Pharma)

• aurora biopharmacy

• Autolus therapeutics

• forward

• Avecia Biologicals

• Avid Bioservices

• AVROBIO

• Gene therapies with Axovant

• bamboo therapeutics

• Batavian Biosciences

• Baylor College of Medicine

• BCM Families Foundation

• and biological

• beam therapy

• Beckman Research Institute

• Beijing Biohealthcare Biotechnology

• Beijing doing biomedical

• Beijing HuiNengAn biotechnology

• Beijing Immunochina Medical Science & Technology

• Beijing Mario Biotechnology

• Beijing Sanwater Biological Technology

• Bellicum Pharmaceuticals

• Benitec Biopharmacy

• BIA Separations (Acquired by Sartorius)

• Bioceltech Therapeutics

• 97. BioCentriq (Acquired by GC)

• biogene

• biogenic technology

• BioInvent International

• BioMarin Pharmaceuticals

• Biomayo

• Biomiga

• bionic sight

• BioNTech Innovative Manufacturing Service (formerly known as Eufects)

• Bio-Rad Laboratories

• biodependence

• BioVec Pharma

• Bioverativ

• biovian

• biovision

• Blue Sky BioServices (subsidiary of LakePharma)

• bluebird bio (formerly known as Genetix Pharmaceuticals)

• BMS

• Boehringer Ingelheim BioXcellence

• BoYuan RunSheng Pharma

• Bio Brain Neurotherapy

• Brammer Bio (acquired by Thermo Fisher Scientific)

• National Laboratory of Biosciences of Brazil (LNBio)

• bristol myers squibb

• Cabaletta Biography

• caltech

• Cambridge Gene Therapy

• Therapeutic Candle

• capsugel

• Carina Biotechnology

• carmine therapeutics

• CARsgen Therapeutics

• Cartesian therapeutics

• Casey Eye Institute

• Castle Creek Biological Sciences

• Catalent Biologicals

• Celgene

• Cell and gene therapy catapult

• Cell Biology Laboratories

• Cellectis

• CellGenTech

• Cellular Biomedicine Group

• Cellvec

• celonian

• Celsion

• celiac oncology

• Center for Advanced Medicines

• Regenerative Medicine Marketing Center

• Process Innovation Center

• CEVEC Pharmaceutical

• CG Oncology

• Children’s Medical Research Institute (CMRI)

• Children’s Hospital of Philadelphia

• China Immunotech Biotechnology

• Choroideremia Research Foundation

• Cincinnati Children’s Hospital Medical Center

• hope city

• clean cells

• clinic

• Cobra Biologics (acquired by Charles River Laboratories)

• Cognate BioServices (acquired by Charles River Laboratories)

• CombiGene

• Copernican Therapeutics

• Cornell University

• creative biogene

• Creative Biological Labs

• CSL Behring

• Cytiva (formerly known as GE Healthcare Life Sciences)

• CytoMed Therapeutics

• Cytovance Biologics

• Daiichi Sankyō

• Decibel

• Delphi genetics

• Denali Therapeutics

• DINAQOR

• DNAtrix

• duke university

• Durham

• Therapeutic Dyno

• edit medicine

• ElevateBio

• scientific elixirgen

• Emendo Biotherapeutics

• Emerging biosolutions

• Emory University School of Medicine

• enGene

• Epeius Biotechnologies

• Wandering Gene Therapeutics

• ERYTECH Pharma

• Aster ESCO

• Steve

• eTheRNA immunotherapies

• EUFETS

• Eureka Biotechnology

• Genomics Eurofins

• scientific eurofins

• ExcellGene

• exotera

• Expression therapy

• Eyevensys

• destiny therapy

• FerGene

• FIMA

• FinVector (formerly Ark Therapeutics)

• Five main therapies

• lightning therapy

• flexion therapy

• florida biologix

• Formula Pharmaceuticals

• biotech fortress

• FosunPharma

• Foundation Fight Against Blindness

• Fraunhofer Institute for Toxicology and Experimental Medicine

• Free line therapy

• Fujifilm Diosynth Biotechnologies

• Basic Therapeutics

• G-CON Manufacturing

• GE Healthcare Life Sciences

• GEG technology

• Genable Technologies

• Genecopoeia

• GeneCure Biotechnologies

• GeneDetect

• GeneImmune Biotechnology

• Genelux

• GeneMedicine

• genenta science

• GeneOne Life Sciences

• Geneton

• Hemera Biosciences

• Henan Hualong Biotechnology

• Herantis Pharmacy

• Hitachi Chemical Advanced Therapeutic Solutions

• Others

For more information on this report, please visit https://www.researchandmarkets.com/r/h2zdyx

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900